Cerebrospinal fluid lactate and glutamine are reduced in multiple sclerosis

Objectives – To analyse various metabolites in human cerebrospinal fluid from healthy controls and patients with multiple sclerosis. Patients and methods – Cerebrospinal fluid was obtained from patients by lumbar puncture, frozen, redissolved, and analysed for metabolites by proton nuclear magnetic resonance spectroscopy. Results – Significantly lower values for lactate and glutamine were found in patients with multiple sclerosis in comparison with controls. No significant differences were found between patients with the relapsing‐remitting and chronic progressive forms of the disease for any of the metabolites measured. Conclusion – There is a concomitant reduction in both lactate and glutamine in the cerebrospinal fluid of patients with multiple sclerosis compared to controls. This may be related to altered astrocytic metabolism during the disease. The results clearly show the diagnostic potential of magnetic resonance spectroscopy in diseases such as multiple sclerosis.

[1]  G. Kreutzberg,et al.  Amyloid precursor protein (APP) expression in multiple sclerosis lesions , 1995, Glia.

[2]  A Heerschap,et al.  Standardized method for high-resolution 1H-NMR of cerebrospinal fluid. , 1995, Clinical chemistry.

[3]  A. Walsh,et al.  Cerebrospinal Fluid Interleukin-6 and Its Diagnostic Value in the Investigation of Meningitis , 1995, Annals of clinical biochemistry.

[4]  W. Russell,et al.  Is There a Case for a Virus Aetiology in Multiple Sclerosis? , 1995, Scottish medical journal.

[5]  C. Poser,et al.  The epidemiology of multiple sclerosis: A general overview , 1994, Annals of neurology.

[6]  H. H. Haan,et al.  Effects of Surgery and Asphyxia on Levels of Nucleosides, Purine Bases, and Lactate in Cerebrospinal Fluid of Fetal Lambs , 1994, Pediatric Research.

[7]  A. Schousboe,et al.  Release of α-ketoglutarate, malate and succinate from cultured astrocytes: possible role in amino acid neurotransmitter homeostasis , 1994, Neuroscience Letters.

[8]  F. Fonnum,et al.  NMR Spectroscopy of Cultured Astrocytes: Effects of Glutamine and the Gliotoxin Fluorocitrate , 1994, Journal of neurochemistry.

[9]  A. Schousboe,et al.  Uptake, Release, and Metabolism of Citrate in Neurons and Astrocytes in Primary Cultures , 1994, Journal of neurochemistry.

[10]  A. Schousboe,et al.  NMR spectroscopic study of cell cultures of astrocytes and neurons exposed to hypoxia: Compartmentation of astrocyte metabolism , 1994, Neurochemistry International.

[11]  J. Newcombe,et al.  Low density lipoprotein uptake by macrophages in multiple sclerosis plaques: implications for pathogenesis , 1994, Neuropathology and applied neurobiology.

[12]  A. Thompson,et al.  Magnetic resonance imaging in monitoring the treatment of multiple sclerosis patients: Statistical power of parallel-groups and crossover designs , 1994, Journal of the Neurological Sciences.

[13]  I. Tominaga,et al.  Proton magnetic resonance spectroscopy of cerebrospinal fluid as an aid in neurological diagnosis. , 1994, Biological & pharmaceutical bulletin.

[14]  A. Schousboe,et al.  Metabolism of [U‐13C]Glutamate in Astrocytes Studied by 13C NMR Spectroscopy: Incorporation of More Label into Lactate than into Glutamine Demonstrates the Importance of the Tricarboxylic Acid Cycle , 1993, Journal of neurochemistry.

[15]  A. Schousboe,et al.  Uptake, release and metabolism of alaume in neurons and astrocytes in primary cultures , 1993, Journal of neuroscience research.

[16]  G. Sutherland,et al.  Nuclear magnetic resonance study of cerebrospinal fluid from patients with multiple sclerosis. , 1993, The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques.

[17]  J. Lindon,et al.  600 MHz 1H-NMR spectroscopy of human cerebrospinal fluid: effects of sample manipulation and assignment of resonances. , 1993, Journal of pharmaceutical and biomedical analysis.

[18]  J. Vion-Dury,et al.  CSF and serum metabolic profile of patients with Huntington's chorea: A study by high resolution proton NMR spectroscopy and HPLC , 1993, Neuroscience Letters.

[19]  J. M. Boyce,et al.  Cerebrospinal fluid lactate in meningitis and meningococcaemia. , 1993, The Journal of infection.

[20]  A. J. Hansen,et al.  Lactate and Postischemic Recovery of Energy Metabolism and Electrical Activity in the Isolated Perfused Rat Brain , 1993, Journal of neurosurgical anesthesiology.

[21]  R. Delorenzo,et al.  Cerebrospinal Fluid Lactate Levels and Prognosis in Status Epilepticus , 1991, Epilepsia.

[22]  D. Leibfritz,et al.  Characterization of CNS lesions by using high-resolution 1H MR spectroscopy of CSF: preliminary results. , 1989, AJNR. American journal of neuroradiology.

[23]  A. Schurr,et al.  Lactate-supported synaptic function in the rat hippocampal slice preparation. , 1988, Science.

[24]  J. Kurtzke.  Rating neurologic impairment in multiple sclerosis , 1983, Neurology.

[25]  D. Silberberg,et al.  New diagnostic criteria for multiple sclerosis: Guidelines for research protocols , 1983, Annals of neurology.

[26]  M. Norenberg,et al.  Fine structural localization of glutamine synthetase in astrocytes of rat brain , 1979, Brain Research.

[27]  R. Bland,et al.  Cerebrospinal fluid lactic acid level and pH in meningitis. Aids in differential diagnosis. , 1974, American journal of diseases of children.

[28]  A. Kaasik,et al.  Cerebrospinal fluid metabolic acidosis and brain oxygen supply. Studies in patients with brain infarction. , 1971, Archives of neurology.

[29]  J. Killian.  Lactic acid of normal and pathological spinal fluids. , 1926 .

[30]  H. Lassmann,et al.  Histopathology and the blood–cerebrospinal fluid barrier in multiple sclerosis , 1994, Annals of neurology.

[31]  D. Miller,et al.  Magnetic resonance in monitoring the treatment of multiple sclerosis , 1994, Annals of neurology.

[32]  J. Gore,et al.  Preferential utilization of lactate in neonatal dog brain: in vivo and in vitro proton NMR study. , 1991, Biology of the neonate.

[33]  D. Weiner,et al.  Expression of c-erbB-2 in human pancreatic adenocarcinomas. , 1991, Pathobiology : journal of immunopathology, molecular and cellular biology.

[34]  B.,et al.  Low Density Lipoprotein , 2022 .